Gate Bioscience, a biotechnology company developing a new class of small molecule medicines aiming to eliminate disease-causing proteins at their source, has announced the close of a US$65 million oversubscribed Series B financing. The Series B was led by new investor Forbion and was joined by additional new investor Eli Lilly and Company, as well as existing investors Versant Ventures, Andreessen Horowitz (a16z) Bio + Health, GV, and ARCH Venture Partners.
Latham & Watkins LLP represented Gate Bioscience in the funding round with an Emerging Companies & Growth team led by Bay Area partner Kathleen Wells, with associates Christopher Pham and Jack McKay, and assistance from Wes Dantzler.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.